The studies reviewed by Waters et al. indicated that HAR1A and HAR1B may function as oncogenes or tumor suppressors depending on the cancer type, with their expression levels serving as potential prognostic biomarkers for tumor progression, particularly for gliomas and oral carcinomas [87]. The gene discussed is HAR1B; the disease is central nervous system cancer.